Steven Cohen Adicet Bio, Inc. Transaction History

Point72 Asset Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$5.52 - $9.23 $95,816 - $160,214	17,358 Added 5786.0%	17,658 $101,000
Q4 2022 Feb 14, 2023	SELL	$7.72 - $21.27 $876,482 - $2.41 Million	-113,534 Reduced 99.74%	300 $2,000
Q3 2022 Nov 14, 2022	SELL	$13.43 - $18.74 $148,616 - $207,376	-11,066 Reduced 8.86%	113,834 $1.62 Million
Q2 2022 Aug 15, 2022	SELL	$10.26 - $20.81 $2.8 Million - $5.69 Million	-273,209 Reduced 68.63%	124,900 $1.82 Million
Q1 2022 May 16, 2022	SELL	$11.53 - $19.97 $4.68 Million - $8.1 Million	-405,791 Reduced 50.48%	398,109 $7.95 Million
Q4 2021 Feb 14, 2022	SELL	$7.37 - $17.49 $3.47 Million - $8.24 Million	-471,100 Reduced 36.95%	803,900 $14.1 Million
Q3 2021 Nov 15, 2021	BUY	$6.29 - $9.93 $377,400 - $595,800	60,000 Added 4.94%	1,275,000 $10 Million
Q2 2021 Aug 16, 2021	BUY	$9.19 - $15.93 $1.53 Million - $2.66 Million	166,900 Added 15.92%	1,215,000 $12.5 Million
Q1 2021 May 17, 2021	BUY	$12.12 - $17.17 $12.7 Million - $18 Million	1,048,100 New	1,048,100 $13.7 Million

59.2M

4.2K

6.7K

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $36M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.